000143006 001__ 143006
000143006 005__ 20240229112539.0
000143006 0247_ $$2doi$$a10.1007/s10654-019-00493-7
000143006 0247_ $$2pmid$$apmid:30771035
000143006 0247_ $$2ISSN$$a0393-2990
000143006 0247_ $$2ISSN$$a1573-7284
000143006 0247_ $$2altmetric$$aaltmetric:55603575
000143006 037__ $$aDKFZ-2019-00631
000143006 041__ $$aeng
000143006 082__ $$a610
000143006 1001_ $$0P:(DE-He78)0c11091f5d6e883a9b6029e4ccea5d5c$$aGao, Xu$$b0$$eFirst author$$udkfz
000143006 245__ $$aOxidative stress and epigenetic mortality risk score: associations with all-cause mortality among elderly people.
000143006 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V.$$c2019
000143006 3367_ $$2DRIVER$$aarticle
000143006 3367_ $$2DataCite$$aOutput Types/Journal article
000143006 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1562057823_5822
000143006 3367_ $$2BibTeX$$aARTICLE
000143006 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143006 3367_ $$00$$2EndNote$$aJournal Article
000143006 520__ $$aOxidative stress (OS) has been found to be related to accelerated aging and many aging-related health outcomes. Recently, an epigenetic 'mortality risk score' (MS) based on whole blood DNA methylation at 10 mortality-related CpG sites has been demonstrated to be associated with all-cause mortality. This study aimed to address the association between OS and MS, and to assess and compare their performance in the prediction of all-cause mortality. For 1448 participants aged 50-75 of the German ESTHER cohort study, the MS was derived from the DNA methylation profiles measured by Illumina HumanMethylation450K Beadchip and the levels of two urinary OS markers, 8-isoprostane (8-iso) and oxidized guanine/guanosine [including 8-hydroxy-2'-deoxyguanosine (8-oxo)], were measured by ELISA kits. Associations between OS markers and the MS were evaluated by linear and ordinal logistic regression models, and their associations with all-cause mortality were examined by Cox regression models. Both OS markers were associated with the MS at baseline. The 8-iso levels and MS, but not 8-oxo levels, were associated with all-cause mortality during a median follow-up of 15.1 years. Fully-adjusted hazard ratios (95% CI) were 1.56 (1.13-2.16) for the 4th quartile of 8-iso levels compared with the 1st, 1.71 (1.27-2.29) and 2.92 (2.03-4.18) for the moderate and high MS defined by 2-5 and > 5 CpG sites with aberrant methylation compared with a MS of 0-1, respectively. After controlling for 8-iso levels, the hazard ratios of MS remained essentially unchanged while the association of 8-iso levels with mortality was attenuated. This study demonstrates that OS is highly associated with the epigenetic MS, and the latter at the same time has a higher predictive value for all-cause mortality.
000143006 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143006 588__ $$aDataset connected to CrossRef, PubMed,
000143006 7001_ $$0P:(DE-He78)8218df9f6f41792399cd3a29b587e4e7$$aGào, Xīn$$b1$$udkfz
000143006 7001_ $$0P:(DE-He78)6a8f87626cb610618a60d742677284cd$$aZhang, Yan$$b2$$udkfz
000143006 7001_ $$aHolleczek, Bernd$$b3
000143006 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b4$$udkfz
000143006 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000143006 773__ $$0PERI:(DE-600)2004992-4$$a10.1007/s10654-019-00493-7$$n5$$p451-462$$tEuropean journal of epidemiology$$v34$$x1573-7284$$y2019
000143006 909CO $$ooai:inrepo02.dkfz.de:143006$$pVDB
000143006 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0c11091f5d6e883a9b6029e4ccea5d5c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143006 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8218df9f6f41792399cd3a29b587e4e7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143006 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6a8f87626cb610618a60d742677284cd$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143006 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143006 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143006 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143006 9141_ $$y2019
000143006 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143006 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium
000143006 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J EPIDEMIOL : 2017
000143006 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143006 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143006 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143006 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143006 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143006 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143006 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143006 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143006 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143006 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J EPIDEMIOL : 2017
000143006 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000143006 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000143006 980__ $$ajournal
000143006 980__ $$aVDB
000143006 980__ $$aI:(DE-He78)C070-20160331
000143006 980__ $$aI:(DE-He78)L101-20160331
000143006 980__ $$aUNRESTRICTED